Global Gouty Arthritis Market
Healthcare Services

Gouty Arthritis Market Size Projected To Increase From $3.95 Billion To $5.06 Billion During The Forecast Period

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Gouty Arthritis Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The market for gouty arthritis has experienced robust expansion over the past few years. Projections indicate a shift from $3.69 billion in 2025 to $3.96 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this growth trajectory in the past include evolving dietary habits, the accessibility of non-steroidal anti-inflammatory drugs (NSAIDs), a rise in arthritis diagnoses, the proliferation of rheumatology clinics, and advancements in pain management therapies.

The market for gouty arthritis is poised for substantial expansion over the upcoming years, projecting to reach $5.06 billion by 2030 with a compound annual growth rate of 6.4%. This anticipated surge is driven by a confluence of factors, including an expanding elderly demographic, heightened public understanding of chronic illnesses, proactive measures in arthritis prevention, enhanced patient adherence to treatment regimens, and the increasing implementation of tailored therapeutic strategies for gout. Key developments anticipated during this period encompass a growing incidence of hyperuricemia, a heightened need for sustained condition management, the proliferation of combination therapies, greater use of advanced diagnostic imaging, and the broader adoption of lifestyle modifications for disease control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16070&type=smp

Gouty Arthritis Market Growth Factors Supporting Long-Term Expansion

The escalating rates of obesity are poised to be a significant catalyst for the expansion of the gouty arthritis market in the future. Obesity, defined as a health condition involving excessive accumulation of body fat to a degree that negatively impacts well-being and is commonly assessed via body mass index (BMI), is on the rise. This increase is attributed to greater consumption of calorie-dense, processed foods and a decline in physical activity. Obesity’s link to gouty arthritis stems from its dual effect on uric acid metabolism: it boosts uric acid production while simultaneously impairing the body’s capacity to eliminate it, resulting in the crystallization of uric acid within the joints. Moreover, the added burden of excess weight intensifies stress on joints, thereby worsening the inflammation and discomfort characteristic of gout. Illustrating this trend, data from May 2025, reported by the Office for Health Improvement and Disparities, a UK governmental entity, revealed that between 2023 and 2024, approximately 64.5% of adults aged 18 and above in England were classified as overweight or obese, marking an increase from 64.0% during the 2022–2023 period. Consequently, the growing incidence of obesity is directly fueling the growth trajectory of the gouty arthritis market.

Gouty Arthritis Market Segment Performance And Strategic Opportunities

The gouty arthritis market covered in this report is segmented –

1) By Type: Acute Gouty Arthritis, Chronic Gouty Arthritis

2) By Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Reliever, Corticosteroids, Xanthine Oxidase Inhibitors, Uricosurics, Other Treatments

3) By Diagnosis: Joint Fluid Test, Blood Test, X-Ray Imaging, Ultrasound, Dual Energy Computed Tomography (CT) Scan, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Acute Gouty Arthritis: Monosodium Urate Crystals-Induced Acute Gout, Acute Gout Attack (Intermittent Flares), Severe Acute Gout With Joint Deformities

2) By Chronic Gouty Arthritis: Tophaceous Gout (Presence Of Uric Acid Deposits), Chronic Gout With Joint Damage, Chronic Gout With Renal Complications, Chronic Gout With Comorbidities (Hypertension, Diabetes)

Gouty Arthritis Market Industry Trends Shaping Future Revenue Growth

Companies prominent within the gouty arthritis sector are intensifying their development initiatives for innovative treatments, including corticotropin gel, aiming to deliver superior and focused interventions for managing this ailment. Corticotropin gel, identified alternatively as repository corticotropin injection, represents a refined derivative of adrenocorticotropic hormone (ACTH), applied in the management of diverse inflammatory and autoimmune disorders, gouty arthritis among them. To illustrate, in October 2023, ANI Pharmaceuticals, a pharmaceutical entity based in the United States, secured authorization from the Food and Drug Administration for a new 1-mL vial configuration of Purified Cortrophin Gel. This particular formulation is designated for the supplementary management of select individuals confronting acute gouty arthritis exacerbations. Presently, Cortrophin Gel stands as the sole adrenocorticotropic hormone (ACTH) therapeutic agent sanctioned by the FDA for addressing suitable patients afflicted with acute gouty arthritis flares.

Gouty Arthritis Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the gouty arthritis market are Horizon Therapeutics plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Bristol Myers Squibb, Novartis International AG, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, GlaxoSmithKline plc, Teijin Pharma Ltd, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, JW Pharmaceutical, Arthrosi Therapeutics Ltd, XORTX Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC, InventisBio Co Ltd, Shanton Pharma, Selecta Biosciences Inc, LG Chem Ltd, Protalix BioTherapeutics Inc

Access The Complete Gouty Arthritis Market Report:

https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report

Gouty Arthritis Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the gouty arthritis market in 2025. Europeis expected to be the fastest-growing region in the forecast period. The regions covered in the gouty arthritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model